AU764186B2 - Hesperitin pro-forms with enhanced bioavailability - Google Patents

Hesperitin pro-forms with enhanced bioavailability Download PDF

Info

Publication number
AU764186B2
AU764186B2 AU26309/00A AU2630900A AU764186B2 AU 764186 B2 AU764186 B2 AU 764186B2 AU 26309/00 A AU26309/00 A AU 26309/00A AU 2630900 A AU2630900 A AU 2630900A AU 764186 B2 AU764186 B2 AU 764186B2
Authority
AU
Australia
Prior art keywords
acid salt
pro
moiety
group
hesperetin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU26309/00A
Other languages
English (en)
Other versions
AU2630900A (en
Inventor
Jan E. Zielinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZIELINSKI LABORATORY
Original Assignee
ZIELINSKI LAB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZIELINSKI LAB filed Critical ZIELINSKI LAB
Publication of AU2630900A publication Critical patent/AU2630900A/en
Application granted granted Critical
Publication of AU764186B2 publication Critical patent/AU764186B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
AU26309/00A 1999-01-27 2000-01-26 Hesperitin pro-forms with enhanced bioavailability Ceased AU764186B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11756799P 1999-01-27 1999-01-27
US60/117567 1999-01-27
US11819899P 1999-02-01 1999-02-01
US60/118198 1999-02-01
PCT/US2000/001923 WO2000044757A1 (en) 1999-01-27 2000-01-26 Hesperitin pro-forms with enhanced bioavailability

Publications (2)

Publication Number Publication Date
AU2630900A AU2630900A (en) 2000-08-18
AU764186B2 true AU764186B2 (en) 2003-08-14

Family

ID=26815410

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26309/00A Ceased AU764186B2 (en) 1999-01-27 2000-01-26 Hesperitin pro-forms with enhanced bioavailability

Country Status (6)

Country Link
EP (1) EP1155021A1 (ja)
JP (1) JP2002535410A (ja)
CN (1) CN1337966A (ja)
AU (1) AU764186B2 (ja)
CA (1) CA2358967A1 (ja)
WO (1) WO2000044757A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4522625B2 (ja) * 2001-09-27 2010-08-11 株式会社ポッカコーポレーション 柑橘属発酵物及びその製造方法
JP4522624B2 (ja) * 2001-09-27 2010-08-11 株式会社ポッカコーポレーション レモン発酵物及びその製造方法
DK1856085T3 (en) * 2005-03-11 2015-10-05 Howard Florey Inst Pty Ltd FLAVONOID COMPOUNDS AND APPLICATIONS THEREOF
BRPI0814876A2 (pt) 2007-07-31 2014-09-30 Limerick Biopharma Inc Análogos de pirona fosforilados e métodos
CN102746264A (zh) * 2012-08-06 2012-10-24 西南大学 7-苯甲氧基橙皮素及其制备方法和用途
CN106565657A (zh) * 2016-11-23 2017-04-19 陕西科技大学 一种具抗肿瘤活性的橙皮素肉桂酸酯类化合物及其合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587176A (en) * 1993-04-20 1996-12-24 The Procter & Gamble Company Methods of using hesperetin for sebum control and treatment of acne
US5763414A (en) * 1996-10-14 1998-06-09 Korea Institute Of Science And Technology Hesperidin and hesperetin as 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587176A (en) * 1993-04-20 1996-12-24 The Procter & Gamble Company Methods of using hesperetin for sebum control and treatment of acne
US5763414A (en) * 1996-10-14 1998-06-09 Korea Institute Of Science And Technology Hesperidin and hesperetin as 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor

Also Published As

Publication number Publication date
AU2630900A (en) 2000-08-18
CN1337966A (zh) 2002-02-27
CA2358967A1 (en) 2000-08-03
WO2000044757A1 (en) 2000-08-03
EP1155021A1 (en) 2001-11-21
JP2002535410A (ja) 2002-10-22

Similar Documents

Publication Publication Date Title
RU2431634C2 (ru) Соединения флавоноидов и их применение
Nie et al. Discovery and anti-diabetic effects of novel isoxazole based flavonoid derivatives
CA2502975A1 (en) Chromones and chromone derivatives and uses thereof
JP2009046486A (ja) ケルセチンのアナログまたは誘導体（プロドラッグ）
PL208242B1 (pl) Pochodna 2-azetydynonu, zawierająca ją farmaceutyczna kompozycja i zastosowanie tej pochodnej, oraz farmaceutyczna kompozycja zawierająca kombinację tej pochodnej i zastosowanie takiej kombinacji
US6699900B2 (en) Hydrophilic and lipophilic silibinin pro-forms
CN101863934B (zh) 水杨酸甲酯糖苷类化合物、其合成方法与用途
AU764186B2 (en) Hesperitin pro-forms with enhanced bioavailability
CN103304573B (zh) 石蒜碱类化合物在制备抗肿瘤药物的应用
US6831098B1 (en) Hesperetin pro-forms with enhanced bioavailablility
CN115385875B (zh) 一类紫杉醇衍生物及其制备方法和用途
CA2569986A1 (en) Compositions and methods of use of dimer digallates
CN103242337B (zh) 一种基于paf/ros双靶点的银杏内酯b衍生物及其制备方法
CN101974016A (zh) 酰胺类化合物及其制备方法和用途
Liu et al. Dihydromyricetin from Ampelopsis grossedentata and its derivatives: Structural characterization and anti-hepatocellular carcinoma activity
US20230055908A1 (en) Mesylate salt of para-topolin, compositions containing said salt and use thereof
CN101857622B (zh) 一种腺苷衍生物及其制备方法和应用
CZ280027B6 (cs) Arylalkylestery 4,5-dihydroxy-9,10-dihyhro-9,10-dioxo-2-anthracenkarboxylových kyselin, způsob výroby a farmaceutické prostředky s jejich obsahem
CN111057036B (zh) 一种香豆素衍生物及其制备方法与应用
CN102260239A (zh) 胡黄连素衍生物及其制备与应用
CN101386607A (zh) 紫杉烷衍生物，其制备方法及应用
CN100395259C (zh) 甾体类衍生物
WO2004063211A1 (en) Carbohydrate derivatives of paclitaxel and docetaxel, method for producing same and use thereof
CN114213381B (zh) 4-色满酮衍生物及其制备方法和医药用途
CN102786458A (zh) 吡咯甲酰胺衍生物、其制备方法和用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)